Palbociclib is an oral drug used to treat some cancers. It is marketed under the name Ibrance. In particular, it can be used in conjunction with other treatments to treat HER2-negative and HR-positive (hormone receptor-positive) breast cancer. By blocking particular molecules involved in cell division, palbociclib acts as a targeted medicine. For patients with particular kinds of breast cancer, this procedure is a crucial therapeutic option since it slows the proliferation of cancer cells.

Palbociclib 125 mg is thoroughly described on this page, along with its mode of action, dose recommendations, adverse effects, and other important details.

Mechanism of Action

Palbociclib belongs to the class of selective inhibitors of cyclin-dependent kinase (CDK) 4/6. The cell cycle’s shift from the G1 phase (cell growth phase) to the S phase (DNA synthesis phase) is specifically driven by CDK4 and CDK6. Palbociclib disturbs the cell cycle and stops cancer cells from multiplying unchecked by blocking these enzymes.

notably vulnerable to disturbances in their cell division cycle are cancer cells, notably those found in HR-positive breast cancer. Palbociclib stops the unchecked proliferation of cancer cells by inhibiting CDK4/6 activity, which makes other treatments more effective. For better treatment results, palbociclib is frequently used in conjunction with letrozole or aromatase inhibitors.

Indications

The main indication for palbociclib is the treatment of HR-positive, HER2-negative breast cancer, which is a prevalent subtype of the disease. This type of breast cancer does not overexpress the HER2 gene, but it does test positive for hormone receptors (progesterone and/or estrogen). Patients are usually recommended 125 mg of palbociclib in the following circumstances:

as a first-line treatment for postmenopausal women with HR-positive, HER2-negative breast cancer, in combination with an aromatase inhibitor such as letrozole.

In conjunction with aromatase inhibitors or letrozole for patients with metastatic or advanced breast cancer.

For women who are premenopausal or who have advanced or metastatic illness, in conjunction with letrozole or letrozole with palbociclib.

Palbociclib effectively inhibits CDK4/6, allowing for prolonged stability and slowing the disease’s course.

Dosage and Administration

For the majority of patients, 125 mg of palbociclib should be given orally with food once daily. Patients usually follow a 28-day treatment plan, taking the medication for 21 days in a row and then taking a 7-day break. Until the condition worsens or unmanageable side effects appear, this cycle is repeated.

There are many strengths of palbociclib pills, including 125 mg. Patients should take their medications precisely as directed. Depending on how the patient reacts to the drug and whether side effects occur, dosage changes can be required. For instance, the dosage may be lowered or the treatment cycle modified if serious adverse effects like neutropenia (low white blood cell count) materialize.

Patients should not break or crush the tablets; instead, they should swallow the medication whole. Patients should take the missed dose as soon as possible, unless the following dose is almost due. They should then proceed with the usual dosing plan and skip the missed dose.

Side Effects

Palbociclib 125 mg may have adverse effects, just like any other medicine. Each person may experience side effects of varying types and intensities. Typical adverse effects include:

The most frequent and sometimes dangerous adverse effect that can raise the risk of infections is neutropenia, or low white blood cell count.

Fatigue: A common feeling of weakness or exhaustion is experienced by many patients.

Vomiting and Nausea: These two gastrointestinal symptoms are very commonly reported.

Anemia: A decrease in red blood cells that causes weakness, paleness, and exhaustion.

Infections: Patients may be more vulnerable to infections as a result of neutropenia’s weakening of the immune system.

Hair thinning or loss: While total hair loss is less common, some individuals notice hair thinning.

Diarrhea: An upset stomach that can lead to discomfort or dehydration.

Healthcare professionals may prescribe therapies to reduce symptoms, and the majority of side effects are controllable. However, some severe adverse effects may necessitate changing the dosage or stopping the medication.

Precautions and Warnings

Patients should disclose any underlying problems or medical history to their healthcare providers prior to beginning Palbociclib. Among the crucial factors to take into account are:

Suppression of bone marrow: Palbociclib may result in bone marrow suppression, which raises the risk of bleeding, anemia, and infection.

Liver issues: Because palbociclib can impact liver function, patients with pre-existing liver diseases should be continuously monitored.

Pregnancy and lactation: Because palbociclib may harm a growing fetus, it is not recommended during pregnancy. Additionally, it shouldn’t be used during nursing.

Drug interactions: Strong CYP3A inducers or inhibitors are among the drugs that palbociclib may interact with. All medications, including over-the-counter pharmaceuticals and vitamins, should be disclosed to patients’ physicians.

Conclusion

For individuals with HR-positive, HER2-negative breast cancer, palbociclib 125 mg is an effective, focused treatment. When used with other treatments like letrozole, it successfully slows the growth of cancer and improves outcomes by blocking CDK4/6. Although the medication may have adverse effects, these can usually be controlled with proper monitoring and dosage modifications.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of palbociclib?
A targeted therapy pill called palbociclib is used in conjunction with other drugs to treat specific forms of breast cancer, especially HER2-negative, HR-positive breast cancer. It functions by blocking CDK4 and CDK6, two cyclin-dependent kinases that promote the growth of cancer cells.

2. How does one administer palbociclib?
Tablets containing palbociclib are administered orally. The typical dosage is 125 mg once daily for 21 days, followed by a 7-day respite (28-day cycle). Food should be consumed with it.

3. What happens if I forget to take my Palbociclib dose?
Take the missed dose as soon as you remember, unless your next dose is almost due. If so, omit the missed dose and take the next one at the appointed time. To make up for a missed dose, avoid taking two doses at once.

4. What are some typical Palbociclib side effects?
Palbociclib frequently causes mouth sores, diarrhea, low white blood cell counts (which raise the risk of infection), nausea, and exhaustion. It’s critical to keep an eye out for any unusual bleeding or indications of infection.

5. Is it possible to combine palbociclib with other medications?
Yes, palbociclib is commonly used to treat HR-positive breast cancer in conjunction with aromatase inhibitors (like letrozole) or other hormonal treatments.